BRII Biosciences published research data on the therapeutic vaccine BRII-179 for the combination therapy of hepatitis B
BRII Pharmaceuticals (02137.HK) announced that its therapeutic vaccine BRII-179 is currently undergoing a Phase II study in the Asia-Pacific region for a sequential combination treatment strategy for hepatitis B virus (HBV). The latest data from this study was recently presented at the American Association for the Study of Liver Diseases (AASLD) liver conference held in the United States.
To further clarify the role of BRII-179 in the treatment of HBV infection and optimize the combination therapy of key studies, the company is conducting two additional Phase IIb studies, both of which have completed patient recruitment and are expected to announce EOT data in 2026
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments